• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在杜普伊特伦挛缩症纤维化中,I型胶原同三聚体的活性合成不受抗TNF-α治疗的影响。

Active synthesis of type I collagen homotrimer in Dupuytren's fibrosis is unaffected by anti-TNF-α treatment.

作者信息

Williamson Kate, Lee Katie J, Beamish Emma L, Carter Alan, Gumbs Jade A, Cooper Gabriella, O'Heneghan-Yates Niamh S, Menezes Lisa A, Cheung Graham, Brown Daniel, Pettitt Rob, Geraghty Brendan, Bosworth Lucy A, Comerford Eithne J, Clegg Peter D, Canty-Laird Elizabeth G

机构信息

Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, William Henry Duncan Building, Liverpool, United Kingdom.

The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing (CIMA), William Henry Duncan Building, Liverpool, United Kingdom.

出版信息

JCI Insight. 2025 May 8;10(9). doi: 10.1172/jci.insight.175188.

DOI:10.1172/jci.insight.175188
PMID:40337865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12128996/
Abstract

Dupuytren's disease is a common fibroproliferative disease of the palmar fascia of the hand, with advanced cases treated surgically. Anti-TNF injection has undergone phase 2 trials and may be effective in slowing early-stage disease progression. Here we sought to determine how new synthesis of type I collagen in Dupuytren's differs from normal palmar fascia samples and to analyze the role of TNF in aberrant collagen synthesis. Model nonfibrotic but fibrous connective tissues were used to analyze active type I collagen protein synthesis in development, aging, and degenerative disease, where it was restricted to early development and ruptured tissue. Dupuytren's tissue was shown to actively synthesize type I collagen, including abnormal type I collagen homotrimer. TNF-α reduced COL1A2 gene expression only in the presence of serum in 2D cell culture and had opposing effects on collagen protein production in the presence or absence of serum. TNF-α had only limited effects in 3D tendon-like constructs. Anti-TNF did not reduce type I collagen synthesis in 3D tendon-like constructs or prevent type I collagen homotrimer synthesis in Dupuytren's tissue. Hence, modulation of the TNF-α pathway in Dupuytren's disease is unlikely to prevent the pathological collagen accumulation that is characteristic of fibrosis.

摘要

杜普伊特伦挛缩病是一种常见的手部掌腱膜纤维增生性疾病,晚期病例采用手术治疗。抗TNF注射已进行了2期试验,可能对减缓疾病早期进展有效。在此,我们试图确定杜普伊特伦挛缩病中I型胶原蛋白的新合成与正常掌腱膜样本有何不同,并分析TNF在异常胶原蛋白合成中的作用。使用模型非纤维化但纤维化的结缔组织来分析发育、衰老和退行性疾病中活性I型胶原蛋白的合成,在这些疾病中,其合成仅限于早期发育和破裂组织。结果显示,杜普伊特伦挛缩病组织能积极合成I型胶原蛋白,包括异常的I型胶原蛋白同三聚体。在二维细胞培养中,TNF-α仅在有血清存在时降低COL1A2基因表达,并且在有或无血清存在时对胶原蛋白的产生有相反的影响。TNF-α在三维肌腱样构建物中的作用有限。抗TNF不能减少三维肌腱样构建物中I型胶原蛋白的合成,也不能阻止杜普伊特伦挛缩病组织中I型胶原蛋白同三聚体的合成。因此,调节杜普伊特伦挛缩病中的TNF-α途径不太可能阻止纤维化特有的病理性胶原蛋白积累。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/960fcd9d369d/jciinsight-10-175188-g179.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/663fb3751f07/jciinsight-10-175188-g178.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/ea84ccb1a376/jciinsight-10-175188-g180.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/971bae311e61/jciinsight-10-175188-g181.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/60972415b142/jciinsight-10-175188-g182.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/14ec3c1a8967/jciinsight-10-175188-g183.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/abdc169043e9/jciinsight-10-175188-g184.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/623606eae26a/jciinsight-10-175188-g185.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/3e7ae53397a9/jciinsight-10-175188-g186.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/088d70fb4a64/jciinsight-10-175188-g187.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/960fcd9d369d/jciinsight-10-175188-g179.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/663fb3751f07/jciinsight-10-175188-g178.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/ea84ccb1a376/jciinsight-10-175188-g180.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/971bae311e61/jciinsight-10-175188-g181.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/60972415b142/jciinsight-10-175188-g182.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/14ec3c1a8967/jciinsight-10-175188-g183.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/abdc169043e9/jciinsight-10-175188-g184.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/623606eae26a/jciinsight-10-175188-g185.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/3e7ae53397a9/jciinsight-10-175188-g186.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/088d70fb4a64/jciinsight-10-175188-g187.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9af9/12128996/960fcd9d369d/jciinsight-10-175188-g179.jpg

相似文献

1
Active synthesis of type I collagen homotrimer in Dupuytren's fibrosis is unaffected by anti-TNF-α treatment.在杜普伊特伦挛缩症纤维化中,I型胶原同三聚体的活性合成不受抗TNF-α治疗的影响。
JCI Insight. 2025 May 8;10(9). doi: 10.1172/jci.insight.175188.
2
Surgery for Dupuytren's contracture of the fingers.手指掌腱膜挛缩症的手术治疗
Cochrane Database Syst Rev. 2015 Dec 9;2015(12):CD010143. doi: 10.1002/14651858.CD010143.pub2.
3
Systematic review of non-surgical treatments for early dupuytren's disease.早期掌腱膜挛缩症非手术治疗的系统评价
BMC Musculoskelet Disord. 2016 Aug 15;17(1):345. doi: 10.1186/s12891-016-1200-y.
4
External Fixation Prior to Fasciectomy Leads to Substantial Improvement of Advanced Dupuytren's PIP Contractures at Mean Follow-up 15 Months.筋膜切除术前行外固定可显著改善平均随访 15 个月的晚期Dupuytren's PIP 挛缩。
Hand (N Y). 2024 Nov;19(8):1293-1299. doi: 10.1177/15589447231175512. Epub 2023 Jun 2.
5
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:系统评价与经济学评估
Health Technol Assess. 2015 Oct;19(90):1-202. doi: 10.3310/hta19900.
6
Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.评估治疗杜普伊特伦挛缩病的最佳功能结局测量指标:系统评价及对未来实践的建议。
BMC Musculoskelet Disord. 2013 Apr 10;14:131. doi: 10.1186/1471-2474-14-131.
7
Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review.掌腱膜挛缩症手术松解术后夹板固定的临床疗效:一项系统评价
BMC Musculoskelet Disord. 2008 Jul 21;9:104. doi: 10.1186/1471-2474-9-104.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

本文引用的文献

1
Collagen (I) homotrimer potentiates the osteogenesis imperfecta (oim) mutant allele and reduces survival in male mice.胶原(I)三聚体增强成骨不全症(oim)突变等位基因,并降低雄性小鼠的存活率。
Dis Model Mech. 2022 Sep 1;15(9). doi: 10.1242/dmm.049428. Epub 2022 Sep 28.
2
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.抗肿瘤坏死因子疗法治疗早期杜普伊特伦挛缩病(RIDD):一项2b期随机双盲安慰剂对照试验
Lancet Rheumatol. 2022 Jun;4(6):E407-E416. doi: 10.1016/S2665-9913(22)00093-5. Epub 2022 Apr 29.
3
A universal multi-platform 3D printed bioreactor chamber for tendon tissue engineering.
一种用于肌腱组织工程的通用多平台3D打印生物反应器腔室。
J Tissue Eng. 2020 Sep 1;11:2041731420942462. doi: 10.1177/2041731420942462. eCollection 2020 Jan-Dec.
4
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.抗 TNF 疗法通过巨噬细胞 IL-10 信号传导发挥其在 IBD 中的治疗作用。
Gut. 2020 Jun;69(6):1053-1063. doi: 10.1136/gutjnl-2019-318264. Epub 2019 Sep 10.
5
Integrative genomic and transcriptomic analysis of genetic markers in Dupuytren's disease.Dupuytren 病遗传标志物的基因组和转录组综合分析。
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):98. doi: 10.1186/s12920-019-0518-3.
6
Dupuytren's disease: where do we stand?掌腱膜挛缩症:我们目前的进展如何?
EFORT Open Rev. 2019 Feb 20;4(2):63-69. doi: 10.1302/2058-5241.4.180021. eCollection 2019 Feb.
7
Recent advances in the understanding of Dupuytren's disease.对掌腱膜挛缩症认识的最新进展。
F1000Res. 2019 Feb 28;8. doi: 10.12688/f1000research.17779.1. eCollection 2019.
8
A cysteine-based molecular code informs collagen C-propeptide assembly.半胱氨酸基分子密码指导胶原蛋白 C 端前肽组装。
Nat Commun. 2018 Oct 11;9(1):4206. doi: 10.1038/s41467-018-06185-2.
9
Treatment of Dupuytren's contracture: a systematic review.掌腱膜挛缩症的治疗:系统评价。
Bone Joint J. 2018 Sep;100-B(9):1138-1145. doi: 10.1302/0301-620X.100B9.BJJ-2017-1194.R2.
10
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.抗肿瘤坏死因子疗法治疗杜普伊特伦挛缩症:一项随机剂量反应概念验证 2a 期临床试验。
EBioMedicine. 2018 Jul;33:282-288. doi: 10.1016/j.ebiom.2018.06.022. Epub 2018 Jul 6.